Skip to main content

Advertisement

SpringerLink
Log in

Scleroderma-like cutaneous syndromes

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Several distinct entities associated with dermal fibrosis can mimic scleroderma/systemic sclerosis. The list of sclerodermalike conditions or scleroderma variants includes eosinophilic fasciitis, localized forms of scleroderma, scleredema and scleromyxedema, keloids, and environmental exposure-associated conditions including eosinophilia-myalgia syndrome and pseudosclerodermas induced by various drugs. Although these conditions are relatively uncommon, their accurate recognition is essential to avoid misdiagnosis and inappropriate therapy. The pathogenesis of these scleroderma variants appears to share similarities with each other and with that of scleroderma. Better understanding of scleroderma-like disorders is emerging through epidemiologic investigations, and in vivo and in vitro experimental research. Activation of eosinophils and disordered regulation of fibroblast collagen synthesis, apoptosis, and proliferation are recurrent findings in these disorders. The etiologic role of infection with Borrelia species or other microorganisms remains controversial. Cytokines such as transforming growth factor-beta, interleukin-4, interleukin-13, and connective tissue growth factor contribute to fibrosis in these disorders by inducing an accentuated and persistent fibrogenic response to tissue injury. The role of genetic factors in susceptibility and clinical expression of scleroderma-like conditions remains to be systematically addressed. Because of the relative rarity of these conditions, few well-controlled clinical treatment trials have been performed. In addition, there is no consensus on optimal management. Much anecdotal information and small clinical series indicate that phototherapy may have a role in the treatment of scleroderma-like conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Varga J, Mori Y, Takagawa S: Pathogenesis of fibrosis. Clin Exp Immunol 2002, In press.

  2. Hitraya EG, Jimenez SA, Ludwicka A, et al.: Increased activity of the a1(I) procollagen promoter in skin fibroblasts from patients with chronic eosinophilia-myalgia syndrome. Int J Biochem Cell Biol 1997, 29:135–141.

    Article  PubMed  CAS  Google Scholar 

  3. Peterson LS, Nelson AM, Su WP, et al.: The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol 1997, 24:73–80.

    PubMed  CAS  Google Scholar 

  4. Fujimoto M, Sato S, Ihn H, et al.: A case of linear scleroderma and myasthenia gravis. J Dermatol 2000, 27:31–34.

    Google Scholar 

  5. Stone J, Franks AJ, Guthrie JA, Johnson MH: Scleroderma "en coup de saber": pathological evidence of intracerebral inflammation. J Neurol Neurosurg Psychiatry 2001, 70:382–385.

    Article  PubMed  CAS  Google Scholar 

  6. Higashi Y, Kanekura T, Fukumaru K, Kanzaki T: Scleroderma en coup de sabre with central nervous system involvement. J Dermatol 2000, 27:486–488.

    PubMed  CAS  Google Scholar 

  7. Torres JE, Sanchez JL: Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol 1998, 20:242–245. An attempt to systematically compare the pathologic features in lesional skin in localized and systemic scleroderma.

    Article  PubMed  CAS  Google Scholar 

  8. Uziel Y, Feldman BM, Krafchik BR, et al.: Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000, 136:91–95.

    Article  PubMed  CAS  Google Scholar 

  9. Seyger MM, van den Hoogen FH, van Vlijmen-Willems IM, et al.: Localized and systemic scleroderma show different histological responses to methotrexate therapy. J Pathol 2001, 193:511–516.

    Article  PubMed  CAS  Google Scholar 

  10. Kamath NV, Usmani A, Pellegrini A: When is surgical treatment not appropriate for morphea? Ann Plast Surg 2000, 45:199–201.

    PubMed  CAS  Google Scholar 

  11. Dutz J: Treatment options for the cutaneous manifestations of systemic sclerosis. Skin Therapy Lett 2000, 6:3–5.

    PubMed  CAS  Google Scholar 

  12. Grundmann-Kollmann M, Ochsendorf F, Zollner TM, et al.: PUVA-cream photochemotherapy for the treatment of localized scleroderma. J Am Acad Dermatol 2000, 43:675–678.

    Article  PubMed  CAS  Google Scholar 

  13. Karrer S, Abels C, Landthaler M, Szeimies RM: Topical photodynamic therapy for localized scleroderma. Acta Derm Venereol 2000, 80:26–27.

    Article  PubMed  CAS  Google Scholar 

  14. Quan T, He T, Voorhees J, Fisher G: Ultraviolet irradiation blocks cellular responses to transforming growth factor-beta by down-regulating its type-II receptor and inducing Smad7. J Biol Chem 2001, 276:26349–26356. This interesting study attempts to provide a mechanistic explanation for the antifibrotic effects of ultraviolet light irradiation of the skin. The results implicate blockage of TGFβ signaling by ultraviolet irradiation in repressing collagen synthesis in the skin.

    Article  PubMed  CAS  Google Scholar 

  15. Elst EF, Van Suijlekom-Smit LW, Oranje AP: Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol 1999, 16:53–58.

    Article  PubMed  CAS  Google Scholar 

  16. Hulshof MM, Bouwes Bavinck JN, Bergman W, et al.: Doubleblind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000, 43:1017–1023.

    Article  PubMed  CAS  Google Scholar 

  17. Cunningham BB, Landells ID, Langman C, et al.: Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998, 39:211–215.

    Article  PubMed  CAS  Google Scholar 

  18. Hunzelmann N, Anders S, Fierlbeck G, et al.: Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 1997, 36:433–435.

    Article  PubMed  CAS  Google Scholar 

  19. Weide B, Walz T, Garbe C: Is morphoea caused by Borrelia burgdorferi? Br J Dermatol 2000, 142:636–644. A critical overview of recent publications that implicate, or fail to implicate, Borrelia infections in the pathogenesis of localized scleroderma.

    Article  PubMed  CAS  Google Scholar 

  20. Arnett FC, Tan FK, Uziel Y, et al.: Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with localized scleroderma. Arthritis Rheum 1999, 42:2656–2659.

    Article  PubMed  CAS  Google Scholar 

  21. McNiff JM, Glusac EJ, Lazova RZ, Carroll CB: Morphea limited to the superficial reticular dermis: an underrecognized histologic phenomenon. Am J Dermatopathol 1999, 21:315–319.

    Article  PubMed  CAS  Google Scholar 

  22. Gilmour TK, Wilkinson B, Breit SN, Kossard S: Analysis of dendritic cell populations using a revised histological staging of morphoea. Br J Dermatol 2000, 143:1183–1192.

    Article  PubMed  CAS  Google Scholar 

  23. Kubo M, Ihn H, Yamane K, Tamaki K: Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001, 44:731–734.

    Article  PubMed  CAS  Google Scholar 

  24. Naschitz JE, Misselevich I, Rosner I, et al.: Lymph-node-based malignant lymphoma and reactive lymphadenopathy in eosinophilic fasciitis. Am J Med Sci 1999, 318:343–349.

    Article  PubMed  CAS  Google Scholar 

  25. Farrell AM, Ross JS, Bunker CB: Eosinophilic fasciitis associated with autoimmune thyroid disease and myelodysplasia treated with pulsed methylprednisolone and antihistamines. Br J Dermatol 1999, 140:1185–1187.

    PubMed  CAS  Google Scholar 

  26. Moriguchi M, Terai C, Kuroki S, et al.: Eosinophilic fasciitis complicated with peripheral polyneuropathy. Intern Med 1998, 37:417–420.

    PubMed  CAS  Google Scholar 

  27. McGrory BJ, Schmidt IU, Wold LE, Amadio PC: Carpal tunnel syndrome associated with eosinophilic fasciitis. Orthopedics 1998, 21:368–370.

    PubMed  CAS  Google Scholar 

  28. Bonnotte B, Chauffert B, Caillot D, Martin F, Lorcerie B: Successful treatment with antithymocyte globulin and cyclosporin A of a severe aplastic anaemia associated with an eosinophilic fasciitis. Br J Rheumatol 1998, 37:1358–1359.

    Article  PubMed  CAS  Google Scholar 

  29. Masuoka H, Kikuchi K, Takahashi S, et al.: Eosinophilic fasciitis associated with low-grade T-cell lymphoma. Br J Dermatol 1998, 139:928–930.

    Article  PubMed  CAS  Google Scholar 

  30. Bohme A, Wolter M, Hoelzer D: L-tryptophan-related eosinophilia-myalgia syndrome possibly associated with a chronic B-lymphocytic leukemia. Ann Hematol 1998, 77:235–238.

    Article  PubMed  CAS  Google Scholar 

  31. Garcia VP, de Quiros JF, Caminal L: Autoimmune hemolytic anemia associated with eosinophilic fasciitis. J Rheumatol 1998, 25:1864–1865.

    PubMed  CAS  Google Scholar 

  32. Florell SR, Egan CA, Gregory MC, et al.: Eosinophilic fasciitis occurring four weeks after the onset of dialysis in a renal failure patient. J Cutan Med Surg 2001, 5:33–36.

    PubMed  CAS  Google Scholar 

  33. Viallard JF, Taupin JL, Ranchin V, et al.: Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis. J Rheumatol 2001, 28:75–80.

    PubMed  CAS  Google Scholar 

  34. Schiener R, Behrens-Williams SC, Gottlober P, et al.: Eosinophilic fasciitis treated with psoralen-ultraviolet A bath photochemotherapy. Br J Dermatol 2000, 142:804–807.

    Article  PubMed  CAS  Google Scholar 

  35. Rongioletti F, Ghigliotti G, De Marchi R, Rebora A: Cutaneous mucinoses and HIV infection. Br J Dermatol 1998, 139:1077–1080.

    Article  PubMed  CAS  Google Scholar 

  36. Rho YW, Suhr KB, Lee JH, Park JK: A clinical observation of scleredema adultorum and its relationship to diabetes. J Dermatol 1998, 25:103–107.

    Article  PubMed  CAS  Google Scholar 

  37. Stables GI, Taylor PC, Highet AS: Scleredema associated with paraproteinaemia treated by extracorporeal photopheresis. Br J Dermatol 2000, 142:781–783.

    Article  PubMed  CAS  Google Scholar 

  38. Hager CM, Sobhi HA, Hunzelmann N, et al.: Bath-PUVA therapy in three patients with scleredema adultorum. J Am Acad Dermatol 1998, 38:240–242.

    Article  PubMed  CAS  Google Scholar 

  39. Jablonska S, Blaszczyk M: Scleromyxedema is a sclerodermalike disorder and not a coexistence of scleroderma with papular mucinosis. Eur J Dermatol 1999, 9:551–554.

    PubMed  CAS  Google Scholar 

  40. Cowper SE, Robin HS, Steinberg SM, et al.: Scleromyxoedemalike cutaneous diseases in renal-dialysis patients. Lancet 2000, 356:1000–1001. An intriguing report describing 15 patients who developed diffuse skin induration associated with hemodialysis treatment. Biopsy of the skin indicated scleromyxedema-like pathologic changes in these patients.

    Article  PubMed  CAS  Google Scholar 

  41. Rongioletti F, Rebora A: Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001, 44:273–281.

    Article  PubMed  CAS  Google Scholar 

  42. Launay D, Hatron PY, Delaporte E, et al.: Scleromyxedema (lichen myxedematosus) associated with dermatomyositis. Br J Dermatol 2001, 144:359–362.

    Article  PubMed  CAS  Google Scholar 

  43. Van Linthoudt D, Schumacher HR Jr, Algeo S, et al.: Scleromyxedema with myopathy and hyperthyroidism. J Rheumatol 1996, 23:1299–1301.

    PubMed  Google Scholar 

  44. Lister RK, Jolles S, Whittaker S, et al.: Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 2000, 43:403–408.

    PubMed  CAS  Google Scholar 

  45. Gonzalez J, Palangio M, Schwartz J, et al.: Scleromyxedema with dermato-neuro syndrome. J Am Acad Dermatol 2000, 42:927–928.

    Article  PubMed  CAS  Google Scholar 

  46. Nieves DS, Bondi EE, Wallmark J, et al.: Scleromyxedema: successful treatment of cutaneous and neurologic symptoms. Cutis 2000, 65:89–92.

    PubMed  CAS  Google Scholar 

  47. Johkura K, Susuki K, Hasegawa O, et al.: Encephalopathy in scleromyxedema. Neurology 1999, 53:1138–1140.

    PubMed  CAS  Google Scholar 

  48. Rayson D, Lust JA, Duncan A, Su WP: Scleromyxedema: a complete response to prednisone. Mayo Clin Proc 1999, 74:481–484.

    Article  PubMed  CAS  Google Scholar 

  49. Tschen JA, Chang JR: Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol 1999, 40:303–307.

    Article  PubMed  CAS  Google Scholar 

  50. Tuan TL, Nichter LS: The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 1998, 4:19–24.

    Article  PubMed  CAS  Google Scholar 

  51. Xue H, McCauley RL, Zhang W: Elevated interleukin-6 expression in keloid fibroblasts. J Surg Res 2000, 89:74–77.

    Article  PubMed  CAS  Google Scholar 

  52. Lee TY, Chin GS, Kim WJ, et al.: Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg 1999, 43:179–184.

    PubMed  CAS  Google Scholar 

  53. Wang R, Ghahary A, Shen Q, et al.: Hypertrophic scar tissues and fibroblasts produce more transforming growth factorbeta1 mRNA and protein than normal skin and cells. Wound Repair Regen 2000, 8:128–137.

    Article  PubMed  CAS  Google Scholar 

  54. Chipev CC, Simman R, Hatch G, et al.: Myofibroblast phenotype and apoptosis in keloid and palmar fibroblasts in vitro. Cell Death Differ 2000, 7:166–176.

    Article  PubMed  CAS  Google Scholar 

  55. Serini G, Gabbiani G: Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 1999, 250:273–283.

    Article  PubMed  CAS  Google Scholar 

  56. Chodon T, Sugihara T, Igawa HH, et al.: Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. Am J Pathol 2000, 157:1661–1669. This intriguing study shows that keloid-derived fibroblasts are relatively resistant to apoptosis induced by Fas in vitro. TGFβ plays a role in this phenomenon because blocking TGFβ with a neutralizing antibody abrogated apoptosis resistance.

    PubMed  CAS  Google Scholar 

  57. Ladin DA, Hou Z, Patel D, et al.: p53 and apoptosis alterations in keloids and keloid fibroblasts. Wound Repair Regen 1998, 6:28–37.

    Article  PubMed  CAS  Google Scholar 

  58. Saed GM, Ladin D, Olson J, et al.: Analysis of p53 gene mutations in keloids using polymerase chain reaction-based single-strand conformational polymorphism and DNA sequencing. Arch Dermatol 1998, 13:963–967.

    Article  Google Scholar 

  59. Luo S, Benathan M, Raffoul W, et al.: Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast Reconstr Surg 2001, 107:87–96.

    Article  PubMed  CAS  Google Scholar 

  60. Tuan T-L, Zhu JY, Sun B, et al.: Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts. J Invest Dermatol 1996, 106:1007–1011.

    Article  PubMed  CAS  Google Scholar 

  61. Oriente A, Fedarko NS, Pacocha SE, et al.: Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000, 292:988–994.

    PubMed  CAS  Google Scholar 

  62. Varga J: Recombinant cytokine treatment for scleroderma: can the antifibrotic potential of interferon-_ be realized clinically? Arch Dermatol 1997, 133:637–642.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Rheumatology, University of Illinois at Chicago College of Medicine, 1158 MBRB, 900 S. Ashland Avenue, 60607-7171, Chicago, IL, USA

    John Varga MD

Authors
  1. Yasuji Mori MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Veli-Matti Kahari MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Varga MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mori, Y., Kahari, VM. & Varga, J. Scleroderma-like cutaneous syndromes. Curr Rheumatol Rep 4, 113–122 (2002). https://doi.org/10.1007/s11926-002-0006-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-002-0006-0

Keywords

Search

Navigation